These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 7592048

  • 1. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
    Higashitani F, Nishida K, Hyodo A, Inoue M.
    J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.
    Kadima TA, Weiner JH.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa.
    Nishida K, Higashitani F, Hyodo A.
    Chemotherapy; 1997 Oct; 43(3):171-8. PubMed ID: 9142457
    [Abstract] [Full Text] [Related]

  • 6. [Development of beta-lactamase inhibitors].
    Hyodo A, Higashitani F, Nishida K, Kunugita C, Unemi N.
    Nihon Rinsho; 1997 May; 55(5):1272-80. PubMed ID: 9155186
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M, Yang Y, Livermore DM.
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [Abstract] [Full Text] [Related]

  • 9. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
    Motohiro T, Nagai K, Yamada T, Oki S, Yamada T, Yoshinaga Y, Tsumura N, Oda K, Sakata Y, Kato H, Imai S, Morita J, Matsuo Y, Ikezawa S, Takahgashi K, Fukuda T, Yamashita Y, Aramaki M, Hayashi M, Yamakawa R, Ono-E, Tananari Y, Tsutsumi T, Hoshuyama A, Aida K.
    Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field].
    Shinagawa N, Yura J, Mashita K, Matsuno S, Rikiyama T, Hirayama T, Tanaka T, Otsuka K, Iwai S, Nakagawa Y.
    Jpn J Antibiot; 1995 Mar; 48(3):346-67. PubMed ID: 7752449
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F, Hyodo A, Ishida N, Inoue M, Mitsuhashi S.
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of YTR 830.
    Jacobs MR, Aronoff SC, Appelbaum PC, Yamabe S.
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [Abstract] [Full Text] [Related]

  • 16. [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
    Duez JM, Siebor E, Pechinot A, Cordin X, Chamard-Neuwirth C, Kazmierczak A.
    Pathol Biol (Paris); 1995 Mar; 43(3):208-14. PubMed ID: 7675548
    [Abstract] [Full Text] [Related]

  • 17. [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration].
    Sato T, Lochry EA, Hoberman AM, Christian MS.
    J Toxicol Sci; 1994 Oct; 19 Suppl 2():199-24. PubMed ID: 7830287
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N, Yamagishi Y, Mikamo H.
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [Abstract] [Full Text] [Related]

  • 20. [Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients].
    Sudo F, Ishiwada N, Hoshino T, Fukasawa C, Inami Y, Hishiki H, Takeda N, Kurosaki T, Kohno Y.
    Kansenshogaku Zasshi; 2005 Sep; 79(9):637-43. PubMed ID: 16248372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.